Publication of Ingrid Struman's team

Our researches, in short for general public:

Two articles summarizing our previous researches are available on the Website of the University of Liege: Reflexions

 

Link to the presentation of our publication on the role of EVs on macrophage reprogramming in tumors

 Notre recherche en quelques mots pour les lecteurs non spécialistes:

Deux articles résumant nos recherches précédentes sont disponibles sur le site de vulgarisation scientifique de l'Université de Liège: Reflexions

Cliquez ici vers la page présentant  notre récente publication sur les role des exosomes dans la re-programmation des macrophages tumoraux

  1. PUBLICATIONS OF THE TEAM:

For an updated publication list of Ingrid Struman in PubMed, click here.

 

To access the publications of Ingrid's team deposited in ORBI (Open Repository of Bibliography) of the University of Liege click here.

  1. 2022

Njock*, M., O’Grady*, T., Nivelles, O., Lion, M., Jacques, S., Cambier, M., Herkenne, S., Muller, F., Christian, A., Remacle, C., Guiot, J., Rahmouni, S., Dequiedt*, F., and Struman*, I. (2022). Endothelial extracellular vesicles promote tumour growth by tumour‐associated macrophage reprogramming. J. Extracell. Vesicles 11. Link

O’Grady*, T., Njock*, M.-S., Lion, M., Bruyr, J., Mariavelle, E., Galvan, B., Boeckx, A., Struman*, I., and Dequiedt*, F. (2022). Sorting and packaging of RNA into extracellular vesicles shape intracellular transcript levels. BMC Biol. 2022 201 20, 1–21.

Zamberlan*, M., Boeckx*, A., Muller, F., Vinelli, F., Ek, O., Vianello, C., Coart, E., Shibata, K., Christian, A., Grespi, F., Giacomello, M., Struman, I., Scorrano*, L., and Herkenne*, S. (2022). Inhibition of the mitochondrial protein Opa1 curtails breast cancer growth. J. Exp. Clin. Cancer Res. 2022 411 41, 1–18.

 

  1. 2021

Fontaine, M., Herkenne, S., Ek, O., Paquot, A., Boeckx, A., Paques, C., Nivelles, O., Thiry, M., and Struman, I. (2021). Extracellular Vesicles Mediate Communication between Endothelial and Vascular Smooth Muscle Cells. J. Mol. Sci. 2022, Vol. 23, Page 331 23, 331.

Parzibut, G., Henket, M., Moermans, C., Struman, I., Louis, E., Malaise, M., Louis, R., Misset, B., Njock, M.S., and Guiot, J. (2021). A Blood Exosomal miRNA Signature in Acute Respiratory Distress Syndrome. Mol. Biosci. 8.

Roblain, Q., Louis, T., Yip, C., Baudin, L., Struman, I., Caolo, V., Lambert, V., Lecomte, J., Noël, A., and Heymans, S. (2021). Intravitreal injection of anti-miRs against miR-142-3p reduces angiogenesis and microglia activation in a mouse model of laser-induced choroidal neovascularization. Aging (Albany. NY). 13, 12359–12377.

 

  1. 2020

Guiot, J., Cambier, M., Boeckx, A., Henket, M., Nivelles, O., Gester, F., Louis, E., Malaise, M., Dequiedt, F., Louis, R., Struman, I*., and Njock, M.-S*. (2020). Macrophage-derived exosomes attenuate fibrosis in airway epithelial cells through delivery of antifibrotic miR-142-3p. Thorax thoraxjnl-2019-214077.

Pérez-Boza, J., Boeckx, A., Lion, M., Dequiedt, F., and Struman, I. (2020). hnRNPA2B1 inhibits the exosomal export of miR-503 in endothelial cells. Cell. Mol. Life Sci.

Francart, M.E., Vanwynsberghe, A.M., Lambert, J., Bourcy, M., Genna, A., Ancel, J., Perez-Boza, J., Noël, A., Birembaut, P., Struman, I., Polette, M., and Gilles, C. (2020). Vimentin prevents a miR-dependent negative regulation of tissue factor mRNA during epithelial–mesenchymal transitions and facilitates early metastasis. Oncogene 39, 3680–3692.

 

  1. 2019

Bonhomme, O., André, B., Gester, F., De Seny, D., Moermans, C., Struman, I., Louis, R., Malaise, M., and Guiot, J. (2019). Biomarkers in systemic sclerosis-associated interstitial lung disease: Review of the literature. Rheumatol. (United Kingdom) 58, 1534–1546.

Guiot, J., Struman, I., Louis, E., Louis, R., Malaise, M., and Njock, M.-S. (2019). Exosomal miRNAs in Lung Diseases: From Biologic Function to Therapeutic Targets. J. Clin. Med. 8, 1345.

  1. 2018

Njock, M.-S., Guiot, J., Henket, M. A., Nivelles, O., Thiry, M., Dequiedt, F., Corhay, J.-L., Louis, R. E. & Struman, I.(2018) Sputum exosomes: promising biomarkers for idiopathic pulmonary fibrosis. Thorax thoraxjnl-2018-211897

Pérez-Boza, J., Lion, M., and Struman, I. (2018). Exploring the RNA landscape of endothelial exosomes. RNA. 24

  1. 2017

Guiot, J., Struman, I., Chavez, V., Henket, M., Herzog, M., Scoubeau, K., Hardat, N., Bondue, B., Corhay, J.L., Moermans, C., and Louis, R. (2017). Altered epigenetic features in circulating nucleosomes in idiopathic pulmonary fibrosis. Clin. Epigenetics 9.

  1. 2016

Blomme, A., Fahmy, K., Peulen, O., Costanza, B., Fontaine, M., Struman, I., Baiwir, D., Pauw, E. de, Thiry, M., Bellahcène, A., Castronovo, V., Turtoi, A., Blomme, A., Fahmy, K., Peulen, O., Costanza, B., Fontaine, M., Struman, I., Baiwir, D., Pauw, E. de, Thiry, M., Bellahcène, A., Castronovo, V., and Turtoi, A. (2016). Myoferlin is a novel exosomal protein and functional regulator of cancer-derived exosomes. Oncotarget 5, 83669–83683.

Frères, P., Wenric, S., Boukerroucha, M., Fasquelle, C., Thiry, J., Bovy, N., Struman, I., Geurts, P., Collignon, J., Schroeder, H., Kridelka, F., Lifrange, E., Jossa, V., Bours, V., Josse, C., and Jerusalem, G. (2016). Circulating microRNA-based screening tool for breast cancer. Oncotarget 7, 5416–5428.

Rambout, X., Detiffe, C., Bruyr, J., Mariavelle, E., Cherkaoui, M., Brohée, S., Demoitié, P., Lebrun, M., Soin, R., Lesage, B., Guedri, K., Beullens, M., Bollen, M., Farazi, T.A., Kettmann, R., Struman, I., Hill, D.E., Vidal, M., Kruys, V., Simonis, N., Twere, J.-C., and Dequiedt, F. (2016). The transcription factor ERG recruits CCR4-NOT to control mRNA decay and mitotic progression. Nat. Struct. Mol. Biol 23, 663–672.

  1. 2015

Herkenne S, Paques C, Nivelles O, Lion M, Bajou K, Pollenus T, Fontaine M, Carmeliet P, Martial JA, Nguyen N-Q-N, Struman I (2015)The interaction of uPAR with VEGFR2 promotes VEGF-induced angiogenesis. Sci Signal 8:ra117–ra117. PMID: 26577922

Bovy, N., Blomme, B., Freres, P., Dederen, S., Nivelles, O., Lion, M., Carnet, O., Martial, J.A., Noel, A., Thiry, M., Jerusalem, G., Josse, C., Bours, V., Tabruyn, S.P., and Struman, I. (2015). Endothelial exosomes contribute to the antitumor response during breast cancer neoadjuvant chemotherapy via microRNA transfer. Oncotarget 6, 10253-10266. PMID: 25860935 access to full text

Freres, P., Josse, C., Bovy, N., Boukerroucha, M., Struman, I., Bours, V., and Jerusalem, G. (2015). Neoadjuvant chemotherapy in breast cancer patients induces miR-34a and miR-122 expression. Journal of cellular physiology 230, 9. PMID: 25078559 access to full text

  1. 2014

Bajou, K., Herkenne, S., Thijssen, V.L., D'Amico, S., Nguyen, N.Q., Bouche, A., Tabruyn, S., Srahna, M., Carabin, J.Y., Nivelles, O., Paques, C., Cornelissen, I., Lion, M., Noel, A., Gils, A., Vinckier, S., Declerck, P.J., Griffioen, A.W., Dewerchin, M., Martial, J.A., Carmeliet, P., and Struman, I. (2014). PAI-1 mediates the antiangiogenic and profibrinolytic effects of 16K prolactin. Nature medicine. PMID: 24929950

Valencia, K., Luis-Ravelo, D., Bovy, N., Anton, I., Martinez-Canarias, S., Zandueta, C., Ormazabal, C., Struman, I., Tabruyn, S., Rebmann, V., De Las Rivas, J., Guruceaga, E., Bandres, E., and Lecanda, F. (2014). miRNA cargo within exosome-like vesicle transfer influences metastatic bone colonization. Molecular oncology 8, 689-703. PMID: 24593875

  1. 2013

Haghikia, A., Podewski, E., Libhaber, E., Labidi, S., Fischer, D., Roentgen, P., Tsikas, D., Jordan, J., Lichtinghagen, R., von Kaisenberg, C.S., Struman, I., Bovy, N., Sliwa, K., Bauersachs, J., and Hilfiker-Kleiner, D. (2013). Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy. Basic research in cardiology 108, 366. PMID: 23812247

Halkein, J., Tabruyn, S.P., Ricke-Hoch, M., Haghikia, A., Nguyen, N.Q., Scherr, M., Castermans, K., Malvaux, L., Lambert, V., Thiry, M., Sliwa, K., Noel, A., Martial, J.A., Hilfiker-Kleiner, D., and Struman, I. (2013). MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy. The Journal of clinical investigation 123, 2143-2154. PMID: 23619365

Lambert, V., Lecomte, J., Hansen, S., Blacher, S., Gonzalez, M.L., Struman, I., Sounni, N.E., Rozet, E., de Tullio, P., Foidart, J.M., Rakic, J.M., and Noel, A. (2013). Laser-induced choroidal neovascularization model to study age-related macular degeneration in mice. Nature protocols 8, 2197-2211. PMID: 24136346

Tabruyn, S.P., Hansen, S., Ojeda-Fernandez, M.L., Bovy, N., Zarrabeitia, R., Recio-Poveda, L., Bernabeu, C., Martial, J.A., Botella, L.M., and Struman, I. (2013). MiR-205 is downregulated in hereditary hemorrhagic telangiectasia and impairs TGF-beta signaling pathways in endothelial cells. Angiogenesis. PMID: 23800974

  1. 2012

D'Amico, S., Martial, J.A., and Struman, I. (2012). A peptide mimicking the C-terminal part of the reactive center loop induces the transition to the latent form of plasminogen activator inhibitor type-1. FEBS Lett 586, 686-692. PMID: 22449964

Detry, B., Erpicum, C., Paupert, J., Blacher, S., Maillard, C., Bruyere, F., Pendeville, H., Remacle, T., Lambert, V., Balsat, C., Ormenese, S., Lamaye, F., Janssens, E., Moons, L., Cataldo, D., Kridelka, F., Carmeliet, P., Thiry, M., Foidart, J.M., Struman, I., and Noel, A. (2012). Matrix metalloproteinase-2 governs lymphatic vessel formation as an interstitial collagenase. Blood 119, 5048-5056. PMID: 22490679

Hilfiker-Kleiner, D., Struman, I., Hoch, M., Podewski, E., and Sliwa, K. (2012). 16-kDa Prolactin and Bromocriptine in Postpartum Cardiomyopathy. Curr Heart Fail Rep. PMID: 22729360

Soares, A.R., Reverendo, M., Pereira, P.M., Nivelles, O., Pendeville, H., Bezerra, A.R., Moura, G.R., Struman, I., and Santos, M.A.S. (2012). Dre-miR-2188 Targets Nrp2a and Mediates Proper Intersegmental Vessel Development in Zebrafish Embryos. PLoS One 7, e39417. PMID:

  1. 2011

Collignon, J., Struman, I., Tabruyn, S., Josse, C., Boukerroucha, M., Jerusalem, G., and Bours, V. (2011). [Molecular and genetic aspects of triple negative breast cancer and therapeutic implications]. Rev Med Liege 66, 393-396. PMID: 21826982

Kinet, V., Castermans, K., Herkenne, S., Maillard, C., Blacher, S., Lion, M., Noel, A., Martial, J.A., and Struman, I. (2011). The angiostatic protein 16K human prolactin significantly prevents tumor-induced lymphangiogenesis by affecting lymphatic endothelial cells. Endocrinology 152, 4062-4071. PMID: 21862622

Nguyen, N.Q., Castermans, K., Berndt, S., Herkenne, S., Tabruyn, S.P., Blacher, S., Lion, M., Noel, A., Martial, J.A., and Struman, I. (2011). The Antiangiogenic 16K Prolactin Impairs Functional Tumor Neovascularization by Inhibiting Vessel Maturation. PLoS One 6, e27318. PMID: 22087289

Sabatel, C., Malvaux, L., Bovy, N., Deroanne, C., Lambert, V., Gonzalez, M.L., Colige, A., Rakic, J.M., Noel, A., Martial, J.A., and Struman, I. (2011). MicroRNA-21 Exhibits Antiangiogenic Function by Targeting RhoB Expression in Endothelial Cells. PLoS One 6, e16979. PMID: 21347332

  1. 2010

Sabatel, C., Cornet, A., Tabruyn, S., Malvaux, L., Castermans, K., Martial, J., and Struman, I. (2010). Sprouty1, a new target of the angiostatic agent 16K prolactin, negatively regulates angiogenesis. Molecular Cancer 9, 231. PMID: doi:10.1186/1476-4598-9-231

Sliwa, K., Blauwet, L., Tibazarwa, K., Libhaber, E., Smedema, J.P., Becker, A., McMurray, J., Yamac, H., Labidi, S., Struman, I., and Hilfiker-Kleiner, D. (2010). Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study. circulation 121, 1465-1473. PMID: 20308616

  1. 2009

Kinet, V., Nguyen, N.Q., Sabatel, C., Blacher, S., Noel, A., Martial, J.A., and Struman, I. (2009). Antiangiogenic liposomal gene therapy with 16K human prolactin efficiently reduces tumor growth. Cancer letters 284, 222-228. PMID: 19473755

Tabruyn, S.P., Memet, S., Ave, P., Verhaeghe, C., Mayo, K.H., Struman, I., Martial, J.A., and Griffioen, A.W. (2009). NF-kappaB activation in endothelial cells is critical for the activity of angiostatic agents. Molecular cancer therapeutics 8, 2645-2654. PMID: 19706735

  1. 2008

Pendeville, H., Winandy, M., Manfroid, I., Nivelles, O., Motte, P., Pasque, V., Peers, B., Struman, I., Martial, J.A., and Voz, M.L. (2008). Zebrafish Sox7 and Sox18 function together to control arterial-venous identity. Dev Biol 317, 405-416. PMID: 18377889

  1. 2007

Erdmann, S., Ricken, A., Merkwitz, C., Struman, I., Castino, R., Hummitzsch, K., Gaunitz, F., Isidoro, C., Martial, J., and Spanel-Borowski, K. (2007). The expression of prolactin and its cathepsin D-mediated cleavage in the bovine corpus luteum vary with the estrous cycle. Am J Physiol Endocrinol Metab 293, E1365-1377. PMID: 17785503

Hilfiker-Kleiner, D., Kaminski, K., Podewski, E., Bonda, T., Schaefer, A., Sliwa, K., Forster, O., Quint, A., Landmesser, U., Doerries, C., Luchtefeld, M., Poli, V., Schneider, M.D., Balligand, J.L., Desjardins, F., Ansari, A., Struman, I., Nguyen, N.Q., Zschemisch, N.H., Klein, G., Heusch, G., Schulz, R., Hilfiker, A., and Drexler, H. (2007a). A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell 128, 589-600. PMID: 17289576

Hilfiker-Kleiner, D., Meyer, G.P., Schieffer, E., Goldmann, B., Podewski, E., Struman, I., Fischer, P., and Drexler, H. (2007b). Recovery from postpartum cardiomyopathy in 2 patients by blocking prolactin release with bromocriptine. J Am Coll Cardiol 50, 2354-2355. PMID: 18068047

Nguyen, N.Q., Cornet, A., Blacher, S., Tabruyn, S.P., Foidart, J.M., Noel, A., Martial, J.A., and Struman, I. (2007). Inhibition of tumor growth and metastasis establishment by adenovirus-mediated gene transfer delivery of the antiangiogenic factor 16K hPRL. Mol Ther 15, 2094-2100. PMID: 17726458

Tabruyn, S.P., Sabatel, C., Nguyen, N.Q., Verhaeghe, C., Castermans, K., Malvaux, L., Griffioen, A.W., Martial, J.A., and Struman, I. (2007). The angiostatic 16K human prolactin overcomes endothelial cell anergy and promotes leukocyte infiltration via nuclear factor-kappaB activation. Mol Endocrinol 21, 1422-1429. PMID: 17405903

  1. 2006

Nguyen, N.Q., Tabruyn, S.P., Lins, L., Lion, M., Cornet, A.M., Lair, F., Rentier-Delrue, F., Brasseur, R., Martial, J.A., and Struman, I. (2006). Prolactin/growth hormone-derived antiangiogenic peptides highlight a potential role of tilted peptides in angiogenesis. Proc Natl Acad Sci U S A 103, 14319-14324. PMID: 16973751

2005 and before

Tabruyn, S.P., Nguyen, N.Q., Cornet, A.M., Martial, J.A., and Struman, I. (2005). The antiangiogenic factor, 16-kDa human prolactin, induces endothelial cell cycle arrest by acting at both the G0-G1 and the G2-M phases. Mol Endocrinol 19, 1932-1942. PMID: 15746189

Pan, H., Nguyen, N.Q., Yoshida, H., Bentzien, F., Shaw, L.C., Rentier-Delrue, F., Martial, J.A., Weiner, R., Struman, I., and Grant, M.B. (2004). Molecular targeting of antiangiogenic factor 16K hPRL inhibits oxygen-induced retinopathy in mice. Invest Ophthalmol Vis Sci 45, 2413-2419. PMID: 15223825

Piwnica, D., Touraine, P., Struman, I., Tabruyn, S., Bolbach, G., Clapp, C., Martial, J.A., Kelly, P.A., and Goffin, V. (2004). Cathepsin D processes human prolactin into multiple 16K-like N-terminal fragments: study of their antiangiogenic properties and physiological relevance. Mol Endocrinol 18, 2522-2542. PMID: 15192082

Tabruyn, S.P., Sorlet, C.M., Rentier-Delrue, F., Bours, V., Weiner, R.I., Martial, J.A., and Struman, I. (2003). The antiangiogenic factor 16K human prolactin induces caspase-dependent apoptosis by a mechanism that requires activation of nuclear factor-kappaB. Mol Endocrinol 17, 1815-1823. PMID: 12791771

Bentzien, F., Struman, I., Martini, J.F., Martial, J., and Weiner, R. (2001). Expression of the antiangiogenic factor 16K hPRL in human HCT116 colon cancer cells inhibits tumor growth in Rag1(-/-) mice. Cancer Res 61, 7356-7362. PMID: 11585777

Corbacho, A.M., Nava, G., Eiserich, J.P., Noris, G., Macotela, Y., Struman, I., Martinez De La Escalera, G., Freeman, B.A., and Clapp, C. (2000). Proteolytic cleavage confers nitric oxide synthase inducing activity upon prolactin. J Biol Chem 275, 13183-13186. PMID: 10788422

Martini, J.F., Piot, C., Humeau, L.M., Struman, I., Martial, J.A., and Weiner, R.I. (2000). The antiangiogenic factor 16K PRL induces programmed cell death in endothelial cells by caspase activation. Mol Endocrinol 14, 1536-1549. PMID: 11043570

Struman, I., Bentzien, F., Lee, H., Mainfroid, V., D'Angelo, G., Goffin, V., Weiner, R.I., and Martial, J.A. (1999). Opposing actions of intact and N-terminal fragments of the human prolactin/growth hormone family members on angiogenesis: an efficient mechanism for the regulation of angiogenesis. Proc Natl Acad Sci U S A 96, 1246-1251. PMID: 9990009

Lee, H., Struman, I., Clapp, C., Martial, J., and Weiner, R.I. (1998). Inhibition of urokinase activity by the antiangiogenic factor 16K prolactin: activation of plasminogen activator inhibitor 1 expression. Endocrinology 139, 3696-3703. PMID: 9724020

D'Angelo, G., Struman, I., Martial, J., and Weiner, R.I. (1995). Activation of mitogen-activated protein kinases by vascular endothelial growth factor and basic fibroblast growth factor in capillary endothelial cells is inhibited by the antiangiogenic factor 16-kDa N-terminal fragment of prolactin. Proc Natl Acad Sci U S A 92, 6374-6378. PMID: 7541539

Goffin, V., Struman, I., Mainfroid, V., Kinet, S., and Martial, J.A. (1994). Evidence for a second receptor binding site on human prolactin. J Biol Chem 269, 32598-32606. PMID: 7798264

Goffin, V., Struman, I., Goormaghtigh, E., and Martial, J.A. (1993). The addition of nine residues at the C-terminus of human prolactin drastically alters its biological properties. Eur J Biochem 214, 483-490. PMID: 8513798

De Moerlooze, L., Struman, I., Renard, A., and Martial, J.A. (1992). Stabilization of T7-promoter-based pARHS expression vectors using the parB locus. Gene 119, 91-93. PMID: 1398095

 

 

  1. Patents

Novel antiangiogenic peptide agents and their therapeutic and diagnostic use WEINER RICHARD I (US); MARTIAL JOSEPH A (BE); STRUMAN INGRID (BE); TAYLOR ROBERT (US); BENTZIEN FRAUKE (US)

Priority date:1997-05-13;Publication number:WO9851323A1, US2008/0090750A1US7,300,920B2.

Patent status A1;

Anti-angiogenic peptides MARTIAL JOSEPH A.(BE), STRUMAN I(BE), NGUYEN NGOC-QUYNH-NHU (BE), BRASSEUR ROBERT (BE), LINS LAURENCE (BE)
Priority date:2004-08-16; Publication number:EP1778724B,US7655626, JP2008509968
Patent status B2
 
A pharmaceutical composition for treatment of thrombosis-related diseases comprising a fragment of prolactin (PRL)-growth hormone (GH)-placental (PL)-family protein
MARTIAL JOSEPH A., STRUMAN I, KHALID BAJOU, D'AMICO SALVINO

Priority date:2010-02-17; Publication number:WO2011/101371A,US20130035289A
Patent status A1

updated on 10/7/24

Share this page

cookieImage